Recorded: February 2022

This webinar discusses key upstream process parameters to consider for efficient and scalable AAV production with a focus on the transfection step.

This webinar will discuss some of the key upstream process parameters to consider for efficient and scalable AAV production with a focus on the transfection step.

Key messages

  • What are the critical upstream parameters for AAV production?​
  • What early process considerations are required to ensure success at large scale?​
  • What high-throughput technologies can accelerate development timelines and deliver a robust platform?​
  • How can innovation drive a fast-changing landscape?

Agenda

  1. What AAV attributes are important to ensure high-yield and high-quality AAV production?
    • Performance and quality attributes: titre, infectivity, E:F, impurities​
    • Cell line/Media importance​
    • Transfection as a critical step: show different approaches are possible and why chemical based is the method of choice​
    • Improvement of AAV production phase: mechanisms to improve titres, lysis vs non lysis and serotype impact.
  2. ​What is Pharmaron’s current approach? ​
    • Platform process and feasibility studies to assess fit (including impact to DSP)​
    • Use of high-throughput technology in combination with DoE to optimise key parameters​
    • Importance of scale-up with a focus on transfection​
    • Pharmaron’s AAV USP platform performance (yield, impurities, infectivity data)​
    • Introduce Polyplus and importance of collaboration​
  3. Collaboration and trial of transfection reagent​
    • Introduction to Polyplus and their products​
    • Presentation of Pharmaron Beta testing data​
    • Presentation of internal Pharmaron data using Polyplus product